LY2365109 is primarily investigated for its potential therapeutic applications in the treatment of various neurological and psychiatric disorders. Its mechanism of action targets specific pathways in the brain, making it a candidate for addressing conditions such as depression, anxiety, and cognitive impairments. Research suggests that it may modulate neurotransmitter systems, potentially improving mood regulation and cognitive function. Additionally, its neuroprotective properties are being explored for potential use in neurodegenerative diseases like Alzheimer's or Parkinson's. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing for these applications. If proven effective, it could offer a novel approach to managing complex brain-related disorders.